Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.

Respiratory medicine·2023
Same author

Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ?

European annals of allergy and clinical immunology·2020
Same author

Pharmacology and Therapeutics of Bronchodilators Revisited.

Pharmacological reviews·2019
Same author

The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement.

Pulmonary pharmacology & therapeutics·2019
Same author

Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways.

Journal of veterinary pharmacology and therapeutics·2018
Same author

Benralizumab for the treatment of asthma.

Drugs of today (Barcelona, Spain : 1998)·2018

Related Experiment Video

Updated: Jun 13, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Indacaterol for chronic obstructive pulmonary disease (COPD).

Mario Cazzola1, A Proietto, M G Matera

  • 1Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome "Tor Vergata", Rehabilitative Pneumology, IRCCS, San Raffaele Pisana, Rome, Italy. mario.cazzola@uniroma2.it

Drugs of Today (Barcelona, Spain : 1998)
|May 15, 2010
PubMed
Summary

Indacaterol, a novel ultra-long-acting beta2-adrenoceptor agonist, offers once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD). Its rapid onset and 24-hour bronchodilation provide an effective option for managing COPD symptoms.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) is a significant global health burden, projected to become the fourth leading cause of mortality by 2030.
  • Current treatments focus on long-term maintenance therapy for airflow obstruction.

Purpose of the Study:

  • To introduce indacaterol (Onbrez), a novel ultra-long-acting beta2-adrenoceptor agonist.
  • To highlight its efficacy and safety profile as a once-daily maintenance bronchodilator for COPD.

Main Methods:

  • Review of indacaterol's pharmacological properties.
  • Analysis of its clinical approval and application in COPD management.

Main Results:

  • Indacaterol provides bronchodilation for at least 24 hours with rapid onset of action.
  • It has demonstrated an optimal safety profile in clinical use.

Conclusions:

  • Indacaterol represents a significant advancement in COPD treatment.
  • Its once-daily dosing, sustained efficacy, and safety profile make it a valuable therapeutic option for patients with chronic obstructive pulmonary disease.